DrugPatentWatch Database Preview
Warner Chilcott Company Profile
What is the competitive landscape for WARNER CHILCOTT, and what generic alternatives to WARNER CHILCOTT drugs are available?
WARNER CHILCOTT has eighty-four approved drugs.
There are five US patents protecting WARNER CHILCOTT drugs.
Summary for Warner Chilcott
| US Patents: | 5 |
| Tradenames: | 42 |
| Ingredients: | 39 |
| NDAs: | 84 |
| Patent Litigation for Warner Chilcott: | See patent lawsuits for Warner Chilcott |
| PTAB Cases with Warner Chilcott as patent owner: | See PTAB cases with Warner Chilcott as patent owner |
Drugs and US Patents for Warner Chilcott
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Warner Chilcott | DURICEF | cefadroxil/cefadroxil hemihydrate | TABLET;ORAL | 050528-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Warner Chilcott Llc | ERYC | erythromycin | CAPSULE, DELAYED REL PELLETS;ORAL | 062338-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Warner Chilcott | DOXYCYCLINE HYCLATE | doxycycline hyclate | TABLET;ORAL | 062593-001 | Aug 28, 1985 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Warner Chilcott | FLURAZEPAM HYDROCHLORIDE | flurazepam hydrochloride | CAPSULE;ORAL | 071767-001 | Dec 4, 1987 | DISCN | No | No | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Warner Chilcott
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Warner Chilcott | ACTONEL WITH CALCIUM (COPACKAGED) | calcium carbonate; risedronate sodium | TABLET, TABLET;ORAL | 021823-001 | Aug 12, 2005 | 5,583,122*PED | ➤ Sign Up |
| Warner Chilcott | ACTONEL WITH CALCIUM (COPACKAGED) | calcium carbonate; risedronate sodium | TABLET, TABLET;ORAL | 021823-001 | Aug 12, 2005 | 6,096,342*PED | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for WARNER CHILCOTT drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Delayed-release Tablets | 200 mg | ➤ Subscribe | 2013-08-12 |
| ➤ Subscribe | Delayed-release Tablets | 80 mg | ➤ Subscribe | 2015-07-01 |
| ➤ Subscribe | Delayed-release Tablets | 150 mg | ➤ Subscribe | 2008-12-19 |
| ➤ Subscribe | Delayed-release Tablets | 200 mg | ➤ Subscribe | 2014-05-19 |
| ➤ Subscribe | Delayed-release Tablets | 50 mg | ➤ Subscribe | 2015-11-05 |
Non-Orange Book US Patents for Warner Chilcott
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 6,225,294 | Method for inhibiting bone resorption | ➤ Sign Up |
| 6,544,967 | Method for inhibiting bone resorption | ➤ Sign Up |
| 6,333,316 | Method for inhibiting bone resorption | ➤ Sign Up |
| 6,569,460 | Film-coated tablet for improved upper gastrointestinal tract safety | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Warner Chilcott Drugs
Supplementary Protection Certificates for Warner Chilcott Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2006002 | Lithuania | ➤ Sign Up | PRODUCT NAME: NATRIUM ALENDRONICUM/COLECACIFEROLUM; REGISTRATION NO/DATE: EU/1/05/310/001, EU/1/05/310/002, EU/1/05/310/003, EU/1/05/310/004, EU/1/05/310/005 20050824 |
| C/GB99/008 | United Kingdom | ➤ Sign Up | PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015 |
| 2016 00016 | Denmark | ➤ Sign Up | PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211 |
| C0062 | France | ➤ Sign Up | PRODUCT NAME: (A) DEXTROMETHORPHAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE BROMHYDRATE DE DEXTROMETHORPHAN ET EN PARTICULIER LE MONOHYDRATE DE BROMHYDRATE DE DEXTROMETHORPHAN (B) QUINIDINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, PAR EXEMPLE LE SULFATE DE QUINIDINE EN PARTICULIER LE DIHYDRATE DE SULFATE DE QUINIDINE; REGISTRATION NO/DATE: EU/1/13/833/001-003 20130626 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
